Categories AlphaGraphs, Earnings, LATEST, Other Industries

Amgen’s stock down despite Q3 results beat

Amgen (AMGN) reported better-than-expected results on revenue and earnings for the third quarter of 2018. After gaining briefly following the results release, shares dropped 0.5% in aftermarket hours.

Total revenues rose 2% to $5.9 billion from the same period last year. Product sales grew 1% globally, with double-digit growth in new products like Repatha, Prolia, KYPROLIS and XGEVA.

Amgen third quarter 2018 Earnings Infographic
Amgen Q3 2018 Earnings Infographic

GAAP net income fell 8% to $1.85 billion while adjusted net income of $2.39 billion remained flat versus the prior-year period. GAAP EPS grew 4% to $2.86 while adjusted EPS increased 13% to $3.69, driven by higher total revenues, lower tax rate and lower weighted-average shares outstanding.

Robert A. Bradway, Chairman and CEO said, “We are in the early stages of launching several new products that offer innovative solutions for patients suffering from serious diseases. Our newer products continue to deliver strong growth in unit volumes.”

Related: Amgen Q3 2018 Earnings Transcript

Amgen posted sales increases for products such as Repatha, Prolia, KYPROLIS, XGEVA, BLINCYTO, Nplate and Vectibix, driven by higher unit demand. Products such as EPOGEN, Enbrel, Neulasta, Aranesp and NEUPOGEN saw sales declines due to lower unit demand and net selling price along with impact from competition.

New drug sales power Amgen’s Q2 results

Amgen revised its guidance for the full year of 2018 and now expects total revenues to be $23.2 billion to $23.5 billion versus the previous range of $22.5 billion to $23.2 billion.

GAAP EPS is expected to be $12.23 to $12.55 versus the previous range of $11.83 to $12.62, and adjusted EPS is expected to be $14.00 to $14.25 versus the prior outlook of $13.30 to $14.00.

Also Read:  Oliver Schusser appointed Vice President of Apple Music

Amgen’s competitor Pfizer (PFE) also reported earnings today. The company beat earnings expectations but missed the mark on revenues.

 

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

With right product mix and CAPEX discipline, Canopy Growth (CGC) can hit growth path

The latest quarterly performance of Canopy Growth Corporation (NYSE: CGC) was nothing short of a disaster, with the cannabis firm incurring a whopping C$1-billion loss in the final months of

Google’s cloud business is well-positioned for growth going forward

Alphabet’s (NYSE: GOOGL) subsidiary Google makes most of its money through its search and advertisement businesses but its cloud division is no small player. This segment is a significant growth

Nio (NIO) picks up speed after hitting COVID-19 roadblock and positions itself for future growth

The coronavirus outbreak impacted the automobile industry as a whole as operations were disrupted and people deferred their vehicle purchases due to a slump in the economy. Overall passenger vehicle

One thought on “Amgen’s stock down despite Q3 results beat

Comments are closed.

Tags

Top